Pfizer Secures Matrix-M License with $30M Upfront, $500M Potential Milestones
Pfizer secured a license for Novavax’s Matrix-M adjuvant with a $30 million upfront payment and up to $500 million in milestones—$70 million for development and $180 million for sales per disease area. The agreement also grants Pfizer royalties on Matrix-M sales for 20 years.
1. License Agreement Terms
Pfizer paid $30 million upfront to license Novavax’s Matrix-M adjuvant and can earn up to $500 million in development and sales milestones, structured as $70 million in development milestones and $180 million in sales milestones for each of two disease areas.
2. Royalty Structure
The agreement includes royalties on Matrix-M sales for 20 years, providing Pfizer with long-term revenue-sharing potential from vaccines and treatments utilizing the adjuvant platform.
3. Strategic Pipeline Expansion
Matrix-M integration allows Pfizer to enhance its vaccine offerings in at least two disease areas, leveraging Novavax’s adjuvant proven in COVID-19 vaccines and exploring new formulations like dry powder to strengthen its R&D pipeline.